CPG 10101

a potent and selective unmethylated cytidine-phosphate-guanosine (CpG)-containing oligodeoxynucleotide agonist of Toll-like receptor 9 (TLR9) for the treatment of chronic infections such as HCV

Also Known As:

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Davis, Heather L: 2 articles (11/2007 - 01/2007)
2.	Efler, Susan M: 2 articles (11/2007 - 01/2007)
3.	Afdhal, Nezam H: 1 article (11/2007)
4.	Al-Adhami, Mohammed: 1 article (11/2007)
5.	Bacon, Bruce R: 1 article (11/2007)
6.	Gordon, Stuart C: 1 article (11/2007)
7.	Jacobson, Ira M: 1 article (11/2007)
8.	Lawitz, Eric: 1 article (11/2007)
9.	Lekstrom-Himes, Julie A: 1 article (11/2007)
10.	McHutchison, John G: 1 article (11/2007)

Related Diseases

1.	Persistent Infection 01/01/2007 - "This study warrants further investigation of CPG 10101 for the treatment of chronic infections such as HCV." 11/01/2007 - "CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. " 01/01/2007 - "CPG 10101 (ACTILON) is a novel potent and selective unmethylated cytidine-phosphate-guanosine (CpG)-containing oligodeoxynucleotide agonist of Toll-like receptor 9 (TLR9) being developed for the treatment of chronic infections such as HCV. "
2.	Chronic Hepatitis C 11/01/2007 - "Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus."
3.	Infections 11/01/2007 - "The data support further clinical studies of CPG 10101 for treating chronic HCV infection."

Related Drugs and Biologics

1.	Toll-Like Receptor 9
2.	Oligodeoxyribonucleotides
3.	CPG 10101
4.	Phosphates (Orthophosphate)
5.	Guanosine
6.	Cytidine
7.	Antiviral Agents (Antivirals)